Gallo A, Rosenbaum D, Kanagasabapathy C, Girerd X
Preventive cardiovascular unit, institute of cardiometabolism and nutrition,ICAN, groupe hospitalier universitaire Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris,75651 Paris cedex 13, France; Inserm 1146, CNRS 7371, laboratoire d'imagerie biomédicale, Sorbonne universités, UPMC univiversité Paris 06, 75013 Paris, France.
Preventive cardiovascular unit, institute of cardiometabolism and nutrition,ICAN, groupe hospitalier universitaire Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris,75651 Paris cedex 13, France; Inserm 1146, CNRS 7371, laboratoire d'imagerie biomédicale, Sorbonne universités, UPMC univiversité Paris 06, 75013 Paris, France; Imaging Core Lab, institute of cardiometabolism and nutrition, ICAN, 75651 Paris cedex 13, France.
Ann Cardiol Angeiol (Paris). 2017 Jun;66(3):165-170. doi: 10.1016/j.ancard.2017.04.007. Epub 2017 May 26.
Baroreceptor activation therapy (BAT) leads to a decrease in blood pressure (BP) in patients affected by resistant hypertension (RH) by reducing sympathetic outflow. This study aimed at evaluating the effects of BAT on RH patients' retinal arteriolar microvasculature, a territory devoid of adrenergic innervation.
Five patients defined as affected by RH after excluding secondary causes of hypertension and based on number of antihypertensive treatments, underwent the implantation of Barostim™ neo™. Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) were assessed by office and 24-hours ambulatory BP monitoring (ABPM). Adaptive Optics Camera RTX1 (ImagineEye, Orsay, France) was used to measure wall thickness (WT), internal diameter (ID), wall cross-sectional area (WCSA) and wall-to-lumen ratio (WLR). A cohort of 21 not-controlled hypertensive patients matched for age, gender and follow-up time, undergoing standard-antihypertensive therapy changes, was selected as a control group. SBP and DBP were assessed by office and home BP monitoring (HBPM). Evaluations were performed at baseline and after 6 months mean follow-up.
Office SBP decreased by 9.7±12.3% and 29.7±12.4% in standard-therapy and BAT group respectively, while office DBP decreased by 7.6±17.4% and 14.8±15.7%. Concerning ABPM/HBPM, a mean reduction of both SBP and DBP of 7.9±11% was observed for the standard-therapy while a reduction of 15.8±10.5% and 15.8%±5.3% was observed for SBP and DBP respectively in BAT group. While in the standard-therapy group a significant reduction in WLR (-5.9%) due to both ID increase (+2.3%) and WT reduction (-5.7%) was observed, without changes in WCSA (-0.3%), RH patients had a significant reduction in WCSA (-12.1%), due to a trend in both WT and ID reduction (-6.5% and -1.7% respectively), without significant changes in WLR (-2%).
While a reverse eutrophic remodeling was observed in patients undergoing a standard-antihypertensive treatment, hypotrophic changes were found in RH patients undergoing BAT. Despite the lack of adrenergic receptors on retinal vessels, chronic baroreflex stimulation may exert an effect on retinal microvasculature in RH patients by more systemic than local mechanisms.
压力感受器激活疗法(BAT)通过减少交感神经输出,使顽固性高血压(RH)患者的血压(BP)降低。本研究旨在评估BAT对RH患者视网膜小动脉微血管系统的影响,该区域缺乏肾上腺素能神经支配。
5例排除高血压继发原因且根据抗高血压治疗次数定义为RH的患者,接受了Barostim™ neo™植入术。通过诊室血压测量和24小时动态血压监测(ABPM)评估收缩压(SBP)和舒张压(DBP)。使用自适应光学相机RTX1(ImagineEye,法国奥赛)测量血管壁厚度(WT)、内径(ID)、血管壁横截面积(WCSA)和壁腔比(WLR)。选择21例年龄、性别和随访时间匹配的未控制高血压患者作为对照组,这些患者接受标准抗高血压治疗调整。通过诊室血压测量和家庭血压监测(HBPM)评估SBP和DBP。在基线和平均随访6个月后进行评估。
在标准治疗组和BAT组中,诊室SBP分别下降了9.7±12.3%和29.7±12.4%,诊室DBP分别下降了7.6±17.4%和14.8±15.7%。关于ABPM/HBPM,标准治疗组的SBP和DBP平均下降了7.9±11%,而BAT组的SBP和DBP分别下降了15.8±10.5%和15.8%±5.3%。在标准治疗组中,由于内径增加(+2.3%)和血管壁厚度降低(-5.7%),壁腔比显著降低(-5.9%),而血管壁横截面积无变化(-0.3%);RH患者的血管壁横截面积显著降低(-12.1%),这是由于血管壁厚度和内径均呈下降趋势(分别为-6.5%和-1.7%),壁腔比无显著变化(-2%)。
在接受标准抗高血压治疗的患者中观察到反向的营养过剩重塑,而在接受BAT的RH患者中发现了营养不足的变化。尽管视网膜血管上缺乏肾上腺素能受体,但慢性压力反射刺激可能通过比局部机制更具全身性的机制对RH患者的视网膜微血管系统产生影响。